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Abstract
Summary—To develop consensus on improving the management of patients, we convened an 
international workshop involving patients, clinicians, and researchers. Key findings included the 
diagnostic delay and variability in subsequent management with agreement to develop an 
international natural history study. We now invite other stakeholders to join the partnership.
Purpose—The aim of this study was develop a consensus on how to improve the management of 
patients with fibrous dysplasia and prioritize areas for research
Methods—An international workshop was held over 3 days involving patients, clinicians, and 
researchers. Each day had a combination of formal presentations and facilitated discussions that 
focused on clinical pathways and research.
The authors are grateful to all clinicians, researchers, and key patient representatives of the FD/MAS partnership for their 
contributions to this paper.
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Results—The patient workshop day highlighted the variability of patients’ experience in getting 
a diagnosis, the knowledge of general clinical staff, and understanding long-term outcomes. The 
research workshop prioritized collaborations that improved understanding of the contemporary 
natural history of fibrous dysplasia/McCune-Albright syndrome (FD/MAS). The clinical 
workshop outlined the key issues around diagnostics, assessment of severity, treatment and 
monitoring of patients.
Conclusions—In spite of advances in understanding the genetic and molecular underpinnings of 
fibrous dysplasia/McCune-Albright syndrome, clinical management remains a challenge. From the 
workshop, a consensus was reached to create an international, multi-stakeholder partnership to 
advance research and clinical care in FD/MAS. We invite other stakeholders to join the 
partnership.
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Introduction
Fibrous dysplasia (OMIM # 174800) is a rare disease affecting the bone and is sometimes 
associated with endocrine dysfunction and skin pigmentation as part of McCune-Albright 
syndrome [1]. Fibrous dysplasia is due to a mosaic mutation during embryogenesis leading 
to constitutive activation of the G-protein alpha subunit in affected tissues including the 
bone, endocrine glands, and skin [2]. Both children and adults report poor physical function 
and pain, but preliminary data suggests that they maintain emotional and social function [3, 
4]. The aims of management are to ensure patients realize their highest quality of life. A 
number of recommendations for the diagnosis [5, 6] and management [6] of patients have 
been published. Management focuses on confirming the diagnosis, determining the extent of 
disease, providing appropriate interventions, and monitoring for complications. This requires 
involvement of a multidisciplinary team across the lifetime of the affected individual. The 
major challenge is to ensure all patients consistently receive high quality care with minimal 
variation.
The aim of this initiative was to develop a global strategy for future research and clinical 
guidance for improving patient outcomes. To facilitate this, we engaged with the Fibrous 
Dysplasia Support Society UK, and the Skeletal Rare Disease Working Group of the 
International Osteoporosis Foundation (SRD-IOF). The SRD-IOF is an international 
working group which focuses on mentoring and knowledge sharing, networking 
opportunities, developing bone-related projects, and initiating advocacy activities and 
integration of skeletal rare diseases of the bone into the general bone.
Method
In order to achieve the aim, a 3-day workshop was convened in conjunction with UK patient 
support society, the Fibrous Dysplasia Support Society (FDSS), the Oxford National 
Institute for Health Research (NIHR) Musculoskeletal Biomedical Research Unit, and the 
NIHR Musculoskeletal Rare Diseases Translational Research Collaboration. The workshop 
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was structured into 3 days: patients with few clinicians on the patient workshop (day 1), both 
patients and clinicians/researchers on the research workshop (day 2), and only clinicians/
researchers on the research workshop (day 3) (agenda in supplementary materials).
Before the meeting, registered participants were sent a brief questionnaire to elicit their 
research priorities across diagnosis, prognosis, and treatment as well as to suggest up to 
three questions for research.
An update on the biology and clinical management for adults and children with fibrous 
dysplasia/McCune-Albright syndrome (FD/MAS) was presented, and patients and their 
family members were invited to comment and discuss their issues either within the wider 
group or in a one-to-one setting with either Dr Collins or Dr Boyce.
For the research workshop, there were presentations of a literature review of all publications 
in PubMED with the MESH term “Fibrous Dysplasia of Bone,” clinical assessment of bone 
pain, health-related quality of life, and costs in patients. The current and proposed activity of 
the International Osteoporosis Foundation Skeletal Rare Disease Clinical Scientific Advisors 
was presented followed by the research activity and key research questions from National 
Institute of Health (NIH), Leiden, Turin, Lyon, Florence, and Oxford. The results from the 
participant survey were next presented. This was followed by a discussion of the priorities 
for research using expert opinion. The final clinical workshop was introduced by state-of-
the-art presentations on pediatric, adult, and surgical management of patients with FD/MAS 
followed by case presentations to stimulate discussion from the experts present on 
developing a global clinical pathway.
Results
Patient workshop
Thirty-seven patients and 33 family members attended the patient workshop with 3 doctors 
present. Following the presentations from doctors, the patients were able to reflect on the 
day and ask questions. The theme of the comments by the patients and family was focused 
on the lack of information for both patients and clinicians and included:
“How do I know what is the right and wrong information on the web?”
“My doctor did tell me I also had FD in the lower arm as well as humerus and was 
told it did not hurt and not to worry about it.”
“Who is going to look after her when she turns 17?”
“The doctor looked at my x-ray of my head and got very excited and said he had 
not seen this before. I felt a bit like a prize cow and the doctor did not want to let 
me go so had to fight to get referred to a Doctor who had seen fibrous dysplasia 
before.”
Following the open session, a series of one-to-one consultations between patients and 
MTC/AMB were undertaken. The feedback from these sessions was wholly positive. 
Patients were encouraged to give details of their case histories and examined when 
necessary. Some were then given suggestions for further diagnostics and treatments.
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Eight patients and 20 academics/clinicians were present. Following short updates on the 
current evidence informing clinical management of fibrous dysplasia, mechanisms of pain in 
the bone, and value of economic assessments, the current and proposed activity of the 
International Osteoporosis Foundation Skeletal Rare Disease Clinical Scientific Advisors 
(website) was presented. The current research activity and key research questions from the 
representative institutions identified a number of existing cohorts as well as two pilot studies 
of denosumab and tociluzimab. The Lyon-developed diagnostic pathway [5] and details 
about the National Institute of Health/National Center for Advancing Translational Sciences 
(NIH/NCATS) Global Rare Diseases Patient Registry Data Repository/GRDRSM were also 
presented.
Ten patients/carers and nine clinicians/researchers responded to the survey. While both 
ranked research into treatment as the highest priority (55 and 65 %, respectively), clinicians/
researchers ranked prognosis (20 %) while patients ranked diagnosis (35 %) as the next 
highest priority.
Several research priorities were identified (Table 1). The highest priority research was 
improving our understanding of the natural history of FD. The method proposed to achieve 
this was aggregation of cohort data already collected in tandem with the development of a 
prospective cohort. The key outputs of the cohort would be to (a) define the natural history, 
(b) determine additional surrogate markers for clinical outcomes (to skeletal disease burden 
score [7] and phosphaturia [8]) and treatment response, and (c) understand the mechanism of 
fibrous dysplasia-related bone pain. From existing datasets, work is needed to identify 
common questions as well as address ethical and governance issues for pooling information 
between countries and working with the GRDR. Of note, the patients’ present felt issues 
around data access were surmountable and were willing to support any ethical issues. One of 
the statements from the patients was their wish for their information to be used for research. 
This was juxtaposed with the researchers concerns not to contravene national data protection 
regulations, and the group felt this had to be carefully balanced lest we overlook the right for 
the patients and their wishes to have their experience shared for the wider good.
An opportunity was identified to learn from existing international consortia that share data, 
such as the international disorders of sex development [9] or the Brittle Bone Disorders 
Consortium (https://www.rarediseasesnetwork.org/cms/BBD). For the prospective cohort, 
key aspects would include tools for pain assessment, fracture history, quality of life (both 
generic and explored disease-specific tools), costs (healthcare, informal, productivity losses, 
social care), standardized radiological imaging, biomarkers for disease activity, and 
standardized tissue biosample-operating procedures. It was recognized that if appropriately 
consented, the cohort could also be offered participation in international clinical trials. The 
group also expressed the need to establish novel research and analytical methodology 
appropriate for rare diseases.
From the post meeting feedback form, 100 % were willing to attend the event again, and 
14/15 thought the format could work for other diseases. In more detail, what can be 
improved: more structured input from patients/have a patient representative speak at the 
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research workshop; representation from orthopedics, craniofacial surgeons, radiologists, 
neurosurgeons, dentists, specialist nurses, geneticists, basic researchers, and radiologists; 
pre-meeting circulation of revised timetable; specific discussion on fertility; and provision of 
a microphone. Other comments included “As a patient it has been humbling to see the level 
of knowledge, skill and passion being directed into FD” (from patient) and “How will the 
international database be used by pharma” (from patient).
Clinical workshop
Fourteen clinicians/clinician scientists and one researcher attended the clinical workshop. 
The rationale and content for the NIH guidance were presented followed by a discussion on 
key orthopedic issues. From the orthopedic presentation (FM), the following concepts were 
discussed: operative and non-operative interventions to improve function, role of 
prophylactic stabilization, bone grafting, assessment of vascularity, and choice of fixation. 
The subsequent discussion was split into pediatric vs. adult and along four themes: 
diagnostics, assessment of severity, treatment and monitoring, and the key issues (Table 2).
From the post meeting feedback, 100 % were willing to attend the event again and thought 
the format could work for other diseases. In more detail, what worked well: clinical cases, 
post lecture discussions/interaction; what could have been improved: communications about 
timing, more cases; other aspects that should have been covered included: indications for 
surgery in adult patients, specialist pain assessment and management, include more 
orthopedic, craniofacial, neurosurgeons and ENT surgeons.
Engagement and communication strategy
It was recognized that a number of centers and clinical specialties were not present, and a 
key next step is to ensure they are invited to join the group. Other aspects of the engagement 
strategy are shown in Table 3.
Discussion
The principal agreement of the meeting was the need for international collaboration to 
improve the evidence base and clinical care for patients with FD/MAS. Another key 
component was the recognition that the current global variation in patient care from 
diagnostics to assessment of severity, management, and monitoring was not evidence-based 
and may also hinder improvement in the evidence base. Finally, the value of a single 
template for evidence-based diagnostic and treatment guidelines and research assessment 
was recognized to enable audit of good practice as well as maximizing collaboration for 
research.
The format of the 3 days worked well by linking a patient day, mixed patient/clinical/
researcher day, and a pure clinical day. The use of clinical cases to stimulate discussion on 
clinical pathways was very successful. While there were specific pediatric and adult sections 
to the day, most attendees participated in both, allowing further sharing of experiences in 
both directions and recognition of the importance of FD/MAS management across the 
lifespan. There was a limited surgical representation and no radiological representation. 
Future meetings will need to address greater orthopedic, craniofacial, and radiologist 
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involvement as well as inviting other centers to join the group. The workshop collated 
opinions from the experts present, and a systematic review was not performed given the low 
number of trials. We also recognize that while a number of patients, family members, and 
carers attended, they may not be representative of the average patient with FD.
In summary, we have described the successful initiation of the international FD/MAS 
partnership that includes clinicians and patients and the methods and outputs from the 
inaugural meeting. We wish to extend the invitation for others to join this partnership to 
support improving outcomes for patients with FD/MAS. For more information please 
contact rudy@ndorms.ox.ac.uk.
Acknowledgments
The workshop was supported by the Oxford NIHR Musculoskeletal BRU, NIHR Rare Diseases Translational 
Research Collaboration, MRC Lifecourse Epidemiology Unit, and International Osteoporosis Foundation. We are 
grateful to ProStrakan for providing funding towards the running costs of the workshop.
References
1. Albright F, Butler MD, Hampton MD, Smith P. Syndrome characterized by osteitis fibrosa 
disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females
— report of five cases. N Engl J Med. 1937; 216:727–746.
2. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations 
of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991; 325(24):
1688–1695. [PubMed: 1944469] 
3. Kelly MH, Brillante B, Kushner H, Gehron Robey P, Collins MT. Physical function is impaired but 
quality of life preserved in patients with fibrous dysplasia of bone. Bone. 2005; 37(3):388–394. 
[PubMed: 15963775] 
4. Kelly MH, Brillante B, Collins MT. Pain in fibrous dysplasia of bone: age-related changes and the 
anatomical distribution of skeletal lesions. Osteoporos Int: J Establish Result Coop Eur Found 
Osteoporos Ntnl Osteoporos Found USA. 2008; 19(1):57–63.
5. Bousson V, Rey-Jouvin C, Laredo JD, Le Merrer M, Martin-Duverneuil N, Feydy A, et al. Fibrous 
dysplasia and McCune-Albright syndrome: imaging for positive and differential diagnoses, 
prognosis, and follow-up guidelines. Eur J Radiol. 2014; 83(10):1828–1842. [PubMed: 25043984] 
6. Boyce, AM., Collins, MT. Fibrous dysplasia/McCune-Albright syndrome. In: Pagon, RA.Adam, 
MP.Ardinger, HH.Wallace, SE.Amemiya, A.Bean, LJH., et al., editors. GeneReviews(R). University 
of Washington; Seattle: 1993. 
7. Collins MT, Kushner H, Reynolds JC, Chebli C, Kelly MH, Gupta A, et al. An instrument to 
measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. J Bone Min 
Res: Off J Am Soc Bone Min Res. 2005; 20(2):219–226.
8. Leet AI, Chebli C, Kushner H, Chen CC, Kelly MH, Brillante BA, et al. Fracture incidence in 
polyostotic fibrous dysplasia and the McCune-Albright syndrome. J Bone Min Res: Off J Am Soc 
Bone Min Res. 2004; 19(4):571–577.
9. Sandberg DE, Callens N, Wisniewski AB. Disorders of sex development (DSD): networking and 
standardization considerations. Horm Metab Res. 2015; 47(5):387–93. [PubMed: 25970713] 
Boyce et al. Page 6
































International cohort to establish natural history and predictors of progression
Mechanisms of bone pain in FD including patient assessment of pain
Harmonize methods for diagnostics, demographics, biochemistry, bone sample processing, and storage
Measurement of quality of life using generic and development of disease-specific tools
Health, social care, and informal costs across the lifespan
Define the spectrum of extraskeletal manifestations in FD/MAS including neuropsychiatric, gastro-intestinal, 
gynecological, and cardiac manifestations
Management RCT of current bone therapies to confirm efficacy
Novel therapies using small molecules
Improving the evidence base for orthopedic and craniofacial surgical indications and techniques
Management of extraskeletal manifestations including long-term gynecologic complications in adults and pancreatic 
involvement
Prognosis Fertility and disease activity during pregnancy
Development of tools to aid in assessment of severity and assist in prognostication

















Diagnostic Importance of isotope bone scintigraphy vs. whole body MR Sensitivity and practicality of whole body MR 
When to delay scintigraphy in children without 
overt bone disease
Role of biopsy and mutation analysis Heterogeneity of lesions affects sensitivity of 
biopsy-based methods
Diagnostic pathways differs between Lyon and NIH Harmonization of diagnostic pathways with 
table of differential diagnoses by site of lesion
Natural history of Mazabraud’s syndrome
Staging Staging evaluation to determine the extent of skeletal and extraskeletal 
involvement should be performed in all patients with suspected disease at 
initial presentation
Evidence-based guidelines to be determined by 
review of existing literature and harmonization 
of the existing NIH and Lyon pathways
Clinical assessment template differs between centers Harmonization of NIH clinical template to 
develop a global clinical template tool. Identify 
key languages for translation
Which diagnostic tests to assess disease severity and extraskeletal 
involvement
Long-term medical vs. surgical management of hyperthyroidism
Role of biochemical testing and pituitary MR in diagnosis and management 
of growth hormone excess
Value of ongoing surveillance for progression of skeletal deformities across 
the lifespan, including scoliosis, hearing and vision deficits, and dental 
complications including mal-occlusions
Management The group acknowledged the importance of defining appropriate indications 
for anti-resorptive therapy
The dose and timing of anti-resorptive therapy varied between sites. The 
group consensus was to identify the maximum dosing for induction therapy 
and then the rationale for the timing of maintenance therapy. Surveillance 
of possible side effects of anti-resorptive therapy (osteonecrosis of the jaw, 
atypical subtrochanteric femoral fractures, hypocalcaemia).
Methods for treatment of hypophosphatemia should be informed by 
pathways in the management of other conditions of FGF23 excess
Use existing guidance for typical and atypical analgesics as well as adjuvant 
interventions in those with chronic pain
Optimizing management of endocrinopathies, including the impact on 
skeletal disease progression and pain
Effects of uncontrolled GH excess on 
craniofacial disease progression. Effects of 
untreated or inadequately treated 
hypophosphatemia on pain and fracture risk. 
Medical therapies are effective for most 
endocrinopathies, and surgical management for 
gonadal disease is not indicated.
Management of craniofacial FD Importance of routine vision and hearing 
monitoring. Prophylactic optic nerve 
decompression in asymptomatic patients is 
contraindicated.
The role of rehabilitation medicine and physiotherapy in management of 
function, deformities, and pain
Guidance for dental health

















Use the IOF to disseminate research and clinical guidelines
Update the Wikipedia pages on fibrous dysplasia and McCune-Albright syndrome
Submit publications in medical, orthopedic, and craniofacial journals
Develop an international network of patient societies and centers of excellence
Produce a patient leaflet that includes information about recommended diagnostic tests, therapies, complications, and research opportunities
Apply for external funding to support the research and clinical network
Plan a meeting for 2016/17
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